- Home
- CGAU vs INVA Comparison
CGAU vs INVA Comparison
Compare CGAU & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | INVA |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 1.7B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CGAU | INVA |
|---|---|---|
| Price | $15.72 | $21.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.00 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 1.7M | 584.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 3.30 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | $23.72 | $8.78 |
| Revenue Next Year | $13.78 | $11.99 |
| P/E Ratio | $11.74 | ★ $6.70 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $5.41 | $16.52 |
| 52 Week High | $21.17 | $25.15 |
Technical Indicators
Market Signals| Indicator | CGAU | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 44.54 |
| Support Level | $10.97 | $20.56 |
| Resistance Level | $20.49 | $21.99 |
| Average True Range (ATR) | 0.92 | 0.51 |
| MACD | -0.43 | -0.15 |
| Stochastic Oscillator | 6.37 | 13.08 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.